For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
To determine if the administration of post-induction age adjusted intrathecal triple chemotherapy on an chemotherapy backbone will improve 5-year DFS of children with high risk B-ALL compared to age adjusted intrathecal methotrexate.
In order to participate you must meet the following criteria:
- Are more than 365 days old and less than 31 years of age.
White blood cell count (WBC) criteria:
- Are 1 to 9.99 years of age: WBC of 50,000/µL
- Are 10 to 30.99 years of age: Any WBC
Are 1 to 30.99 years of age: Any WBC with:
- Testicular leukemia
- CNS leukemia (CNS3)
- Steroid pretreatment
This is a partial list of elgibility requirements.